Brian Hemmings

BIOGRAPHY

CURRENT POSITION:
1990- Senior Group Leader, Friedrich Miescher Institute for Biomedical Research, Basel

EDUCATION
• 1975 PhD, University of East Anglia, Norwich, UK
• 1972 BSc, University of Nottingham, Nottingham, UK

PREVIOUS POSITIONS:
• 1983-1989 Junior Group Leader, Friedrich Miescher Institute for Biomedical Research, Basel
• 1982-1983 FMI Research Associate, The Rockefeller University, New York
• 1980-1982 MRC Research Fellow, Medical Sciences Institute, University of Dundee, Dundee
• 1977-1980 Fogarty Visiting Fellow, NIH, Bethesda, Md., USA
• 1975-1977 Research Fellow, Biochemisches Institut der Universität, Freiburg im Breisgau, Germany

HONORS:
• 2009 Elected Fellow of the Royal Society of London
• 2009 Executive Committee Basel Signaling Alliance
• 2009 Gairdner Foundation Medical Award Subcommittee
• 2004 and 2005 In ISI '100 Most Cited Scientists in Biology and Biochemistry'
• 2004 Novartis Corporate Research Award for Scientific Excellence
• 2004 Swiss Bridge Award
• 2001-2012 Member, Scientific Committee, Swiss Cancer League
• 2000 Cloëtta Prize, Prof Dr Max Cloëtta Foundation, Zurich
• 2000 Japanese Biochemical Society 'JB' award
• 2000 Visiting Professor at the Faculty of Medicine, Katholieke Universiteit, Leuven
• 1999 Philip Godfrey Memorial Lecture of the Biochemical Society Meeting, Glasgow
• 1998-1999 Member, Evaluation Committee, Göran Gustafsson Foundation (The Royal Swedish Academy of Sciences)
• 1996 Member, EMBO
• 1972 Belper Graduation Prize, University of Nottingham, Nottingham

RESEARCH INTERESTS:
Judging simply by the abundance of protein kinase and protein phosphatase genes, protein phosphorylation is a very important regulatory mechanism. Our current work focuses on the role of these enzymes in eukaryotic signaling pathways and their possible implications in human diseases.

Signal transduction pathways in mammalian cells function through the coordinated activation, or inactivation of protein kinases and phosphatases localized in the cell membrane, cytoplasm or nucleus. Many human diseases result from deregulation of signal transduction pathways; for example, the proliferation signal pathways of cancer cells are permanently upregulated following mutation of key regulatory enzymes.

Our current research activities focus on targeting novel kinases involved in the development and progression of glioblastoma, ovarian cancer and lymphoma with the ultimate aim of finding new personalized therapeutic strategies.

HOME PAGE
http://www.fmi.ch/research/groupleader/?group=11